Compare TGE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | LUNG |
|---|---|---|
| Founded | 2023 | 1995 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 57.9M |
| IPO Year | N/A | 2020 |
| Metric | TGE | LUNG |
|---|---|---|
| Price | $1.06 | $1.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 28.8K | ★ 408.3K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $2.99 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.78 | $1.13 |
| 52 Week High | $12.99 | $3.88 |
| Indicator | TGE | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 43.06 |
| Support Level | $1.02 | $1.13 |
| Resistance Level | $1.23 | $1.64 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 11.67 | 19.05 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.